PET/CT fusion in radiotherapy planning for lung cancer – Case reports

Marko dj Erak; Milana Mitrić; Branislav Djuran; Dušanka Tešanović; Sanja Vasiljev

doi:10.2298/VSP140602051E

Marko dj Erak Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
Milana Mitrić Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
Branislav Djuran Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
Dušanka Tešanović Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
Sanja Vasiljev Oncology Institute of Vojvodina, Sremska Kamenica, Serbia

DOI: https://doi.org/10.2298/VSP140602051E

Keywords: carcinoma, non-small-cell lung, radiotherapy, conformal, positron-emission tomography,

Abstract

Introduction. Application of imaging methods, namely computed tomography (CT), magnetic resonance imaging (MRI) and in recent years positron emission tomography/computed tomography (PET/CT), and the progress of computer technology have allowed the construction of effective computed systems for treatment planning (TPS) and introducing the concept of virtual simulation in 3D conformal radiotherapy planning. Case report. We hereby presented two patients with the diagnosis of non-small cell lung cancer who did PET/CT examination. Both patients had surgery earlier and local recidives are diagnosed with PET/CT. PET/CT of the first patient described the focus of intense ¹⁸F-fluorodeoxyglucose (¹⁸FDG) accumulation 2.99 × 2.9 × 2.1cm in diameter in the projection of soft-tissue volume in the left corner, at operating clips height, corresponding to metabolically active recurrence of the tumor. Mediastinum and right lung parenchyma were without focal accumulation of ¹⁸FDG. Control PET/CT after 3 months was without detectable focus of intense pathological ¹⁸FDG accumulation – good therapeutic response, (metabolic disease remission). On the other hand, in the second case PET/CT showed a focus of intense ¹⁸FDG accumulation screening in the scar tissue of the apical part of the right lung, 20 × 16 mm, corresponding to metabolically active tumor recurrence. In the lung parenchyma on the left and in the mediastinum no visible focus of intense ¹⁸FDG accumulation was descrbed. Radiography included using 3D conformal radiotherapy with fusion PET/CT scan and CT simulations. Conclusion. PET/CT provides important information for planning conformal radiotherapy, especially in dose escalation, sparing of organ at risk and better locoregional control of the disease.

Author Biography

Marko dj Erak, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Oncology Institute of Vojvodina, Sremska Kamenica, Serbia

lekar specijalista radiolog subspecijalista onkolog

References

Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother On-col 2006; 81(2): 209−25.

Mac Manus M, Hicks RJ. The use of positron emission tomo-graphy (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys 2008; 72(5): 1298−306.

Paulino A. PET/CT in Radiotherapy Treatment Planning. 1st ed. Philadelphia, PA: Saunders/Elsevier; 2008.

Zhao DS, Valdivia AY, Li Y, Blaufox MD. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med 2002; 32(4): 272−5.

Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA et al. Impact of FDG/PET on radiation therapy volume delin-eation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 59(1): 78−86.

IAEA-TECDOC-1603 The Role of PET/CT in Radiation Treatment Planning for Cancer Patient Treatment. Vienna, Austria: International Atomic Energy Agency; 2008.

Chin R., McCain TW, Miller AA, Dunagan DP, Acostamadiedi J, Harkness AB et al. Whole body FDG/PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002; 37: 1−6.

Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F] FDG/PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2002; 30: 78−84.

Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Sie-gel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004; 22(16): 3248−54.

Wang H, Zhao L, Zhao J, Wang Q.Analysis on Early Detection of Lung Cancer by PET/CT Scan. Asian Pac J Cancer Prev 2015; 16(6): 2215−7.

Huang W, Liu B, Min Fan M, Zhou T, Fu Z, Zhang Z, et al. The early predictive value of a decrease of metabolic tumor volume inrepeated18F-FDG PET/CT for recurrence of locally ad-vanced non-smallcell lung cancer with concurrent radiochemotherapy. Eur J Radiol 2015; 84(3): 482−8.

Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31(12): 1614−20.

Mah K, Caldwell CB, Ung YC, Danjoux CE, Balogh JM, Ganguli SN et al. The impact of (18)FDG/PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002; 52(2): 339−5.

Riegel AC, Bucci MK, Mawlawi OR, Ahmad M, Luo D, Chandler A, et al. Defining internal target volume using positron emission tomography for radiation therapy planning of moving lung tumors. J Appl Clin Med Phys 2014; 15(1): 4600.

Soykut ED, Ozahin EM, Tsoutou PG. The use of PET/CT in radiotherapy planning: contribution of deformable reg-istration. Front Oncol 2013; 3: 33.

Vojtíšek R, Mužík J, Slampa P, Budíková M, Hejsek J, Smolák P, et al. The impact of PET/CT scanning on the size of target vo-lumes, radiation exposure of organs at risk, TCP and NTCP, in the radiotherapy planning of non-small cell lung cancer. Rep Pract Oncol Radiother 2013; 19(3): 182−90.

Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Grégoire V, et al. PET/CT imaging for target volumedelineation in cur-ative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol 2015; pii: S0167-8140(15)00153-X. (In Press)